PointState Capital’s Eli Lilly LLY Stock Holding History

PointState Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,932	Closed	-$6.79M	–	61
2022 Q2	$6.79M	Buy	+20,932	New	+$6.28M	0.17%	41
2022 Q1	–	Sell	-20,000	Closed	-$5.52M	–	102
2021 Q4	$5.52M	Sell	20,000 -20,000	-50%	-$5.07M	0.09%	82
2021 Q3	$9.24M	Sell	40,000 -21,000	-34%	-$5.18M	0.15%	87
2021 Q2	$14M	Buy	61,000 +2,831	+5%	+$569K	0.24%	69
2021 Q1	$10.9M	Sell	58,169 -54,744	-48%	-$10.7M	0.22%	78
2020 Q4	$19.1M	Buy	112,913 +21,187	+23%	+$3.16M	0.36%	58
2020 Q3	$13.6M	Sell	91,726 -83,230	-48%	-$12.9M	0.36%	52
2020 Q2	$28.7M	Buy	174,956 +160,485	+1,109%	+$24.6M	0.87%	27
2020 Q1	$2.01M	Buy	+14,471	New	+$1.99M	0.1%	47
2019 Q2	–	Sell	-31,600	Closed	-$4.1M	–	135
2019 Q1	$4.1M	Buy	+31,600	New	+$3.84M	0.08%	81
2015 Q1	–	Sell	-1,560,106	Closed	-$108M	–	135
2014 Q4	$108M	Buy	+1,560,106	New	+$105M	1.83%	19

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PointState Capital's LLY Position: Q3 2022 in Review

PointState Capital sold out of Eli Lilly (LLY) in Q3 2022, closing a stake of 20,932 shares — an estimated $6.79M sold.

PointState Capital first reported a position in LLY in Q4 2014 and held it in 11 quarters. The position peaked at $108M in Q4 2014. 2,484 funds tracked by Wall St. Rank hold LLY as of Q3 2022.

PointState Capital reported no remaining Eli Lilly position as of Q3 2022 after selling out during the quarter.
PointState Capital sold 20,932 Eli Lilly shares in Q3 2022, an estimated $6.79M.
PointState Capital first reported a position in Eli Lilly in Q4 2014 and held it in 11 quarters.
PointState Capital's Eli Lilly position peaked at $108M in Q4 2014.
2,484 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.

Based on PointState Capital's 13F filing for Q3 2022, filed 10 Nov 2022.